Weight Loss Injections NHS – Eligibility Criteria Guide

The NHS offers weight loss injections to individuals who meet specific medical criteria, including strict body mass index thresholds and weight-related health conditions. These treatments, which include Mounjaro, Wegovy, and Saxenda, are not available through standard GP prescriptions and require referral to specialist weight management services.

Patients seeking access to these medications must navigate a phased rollout system that prioritises those with the highest medical need. The eligibility requirements differ depending on the specific drug, existing health conditions such as type 2 diabetes, and geographic location within the UK.

Understanding the NHS criteria for weight loss injections can help individuals determine whether they might qualify for treatment and what steps to take if they are interested in exploring these options.

What are the NHS criteria for weight loss injections?

The NHS applies stringent eligibility criteria for weight loss injections, focusing on individuals with clinically significant obesity who have not responded to conventional weight management strategies. These criteria include body mass index thresholds, the presence of weight-related comorbidities, and referral to specialist tier 3 weight management services.

Ethnic background influences BMI thresholds, with lower values applying to individuals of Asian, Chinese, Middle Eastern, Black African, or African-Caribbean origin. These adjustments reflect evidence that these populations experience weight-related health risks at lower BMI levels.

• Phased access: Treatment is prioritised for those with the highest medical need, with gradual expansion to wider populations over several years.
• BMI thresholds: Strict requirements range from BMI 30 for Saxenda to BMI 40 for initial Mounjaro access.
• GP referral required: Patients cannot obtain these injections directly from GPs; specialist tier 3 clinic approval is mandatory.
• Comorbidities matter: Conditions such as type 2 diabetes, hypertension, sleep apnoea, or cardiovascular risk can lower eligibility thresholds.
• Treatment duration: Specialist services typically oversee treatment for up to two years with ongoing monitoring.
• Private alternatives exist: Pharmacies such as Boots offer private assessments for those who do not meet NHS criteria.

Who is eligible based on health conditions?

Weight-related health conditions that influence eligibility include type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, and cardiovascular disease risk. Patients with multiple such conditions may qualify at lower BMI thresholds.

For Mounjaro specifically, individuals with a BMI of 40 or above combined with four or more weight-related health conditions represent the initial priority group. This restrictive approach reflects the phased nature of the rollout, which began in March 2025 through specialist services only.

The GP referral process explained

The pathway to NHS weight loss injections begins with a consultation at a GP practice, where a doctor assesses the patient’s BMI, existing health conditions, and previous weight management attempts. If the patient appears to meet initial criteria, the GP refers them to a tier 3 specialist weight management service.

These specialist services, which operate within hospital or community settings, conduct comprehensive assessments before approving treatment. Patients are typically required to demonstrate commitment to lifestyle changes alongside medication use. The specialist team then prescribes and monitors treatment over the approved period, which can extend up to two years.

Is Mounjaro available on the NHS for weight loss?

Mounjaro (tirzepatide) became available on the NHS for weight management through a limited rollout beginning in March 2025. The initial phase prioritised patients with the most severe obesity and multiple weight-related health conditions.

The drug was originally developed and approved for type 2 diabetes management before receiving authorisation for weight loss treatment. This dual indication means that patients with both obesity and diabetes may have different pathway considerations depending on their specific circumstances and local commissioning arrangements.

According to the British Heart Foundation’s analysis of these medications, Mounjaro works by mimicking both GLP-1 and GIP hormones, which helps reduce appetite and food intake more effectively than previous generations of weight loss medications.

Mounjaro rollout timeline and expansion plans

The Mounjaro rollout follows a structured phased approach designed to manage both demand and healthcare capacity. The initial cohort includes patients with a BMI of 40 or above who also have at least four specific weight-related health conditions.

The NHS plans to expand access progressively, with the target of reaching 220,000 patients by 2027 under the expanded criteria of BMI 35 or above with additional health risks. Full rollout to all eligible patients could take between 3 and 12 years depending on resource availability and ongoing clinical outcomes.

Local clinical commissioning groups and integrated care systems are implementing these national guidelines at different paces, meaning patients in some areas may face longer waiting times than others. Herts and West Essex ICS announced expanded access in June 2025 for patients meeting the highest-need criteria.

Comparing Mounjaro with other NHS weight loss injections

Wegovy (semaglutide) has been available on the NHS since September 2023, making it the longest-established of the newer weight loss injection options. It operates by mimicking the GLP-1 hormone to reduce appetite and is typically prescribed alongside diet and exercise support for up to two years.

Saxenda (liraglutide) has the longest history of NHS use among these medications, requiring daily injections rather than weekly doses. Its lower BMI threshold of 30 (or 27 with comorbidities) makes it accessible to a broader patient population compared to the newer agents.

The key differences between these medications relate to their active ingredients, dosing schedules, specific eligibility criteria, and the extent of clinical evidence supporting their use. Treatment selection depends on individual patient factors assessed during specialist consultations.

What are the side effects of weight loss injections on the NHS?

Weight loss injections available through the NHS can produce a range of side effects that patients should understand before starting treatment. These effects relate to the medications’ mechanisms of action, which work by reducing appetite through hormonal pathways.

According to NHS guidance on obesity treatment, common side effects include nausea, vomiting, diarrhoea, and reduced appetite. These symptoms occur because the medications act on digestive hormones that influence hunger signals and stomach emptying.

Managing common side effects

Gastrointestinal symptoms typically occur during the initial weeks of treatment when the body is adjusting to the medication. Many patients find these effects diminish over time as treatment continues. Healthcare teams provide guidance on managing these symptoms, which may include adjusting eating patterns, staying hydrated, and gradual dose titration.

Reduced appetite is an intended effect of these medications but can sometimes become excessive, leading to nutritional concerns. Specialist teams monitor patients for adequate nutritional intake and may adjust treatment if appetite suppression becomes problematic.

Contraindications and who should not use these treatments

Certain medical conditions preclude the use of weight loss injections. Patients with a history of pancreatitis, pregnant individuals, and those with specific thyroid disorders are generally excluded from treatment. A thorough medical assessment at the specialist clinic identifies any contraindications before treatment begins.

These medications require comprehensive medical assessment and are not suitable for everyone with obesity. The decision to prescribe involves careful consideration of potential benefits against individual risk factors, with ongoing monitoring throughout the treatment period.

How does availability differ for weight loss injections in NHS Scotland?

Access to weight loss injections through the NHS in Scotland follows a separate but broadly similar framework to England, with decisions made by the Scottish Medicines Consortium rather than NICE. The Scottish Medicines Consortium has approved Saxenda, Wegovy, and Mounjaro for restricted use within NHS specialist services.

Like England, Scotland requires GP referral to tier 3 specialist weight management services for assessment and prescribing. Services such as NHS Fife and NHS Grampian operate specialist weight management programmes that assess and treat eligible patients within their regions.

Scotland-specific referral pathways

Scottish patients begin their journey through GP referral to one of the specialist weight management services operating across Scotland’s health boards. These services, including those in NHS Fife and NHS Grampian, mirror the tier 3 model used in England but with variations in local implementation.

The rollout of newer medications like Mounjaro is progressing through Scotland’s health service, though the pace may differ from England due to separate commissioning arrangements and devolved healthcare administration. Patients in Scotland can access these treatments where clinically appropriate through specialist services.

Private alternatives across the UK

For patients who do not meet NHS criteria or wish to avoid waiting times, private healthcare options exist. Private clinics offer eligibility assessments for Mounjaro, Wegovy, and Saxenda with different entry requirements than the NHS.

Pharmacy chains including Boots provide private consultations for weight loss injections, typically requiring a BMI of 30 or above (or 27 with comorbidities) and a medical history review. These services are self-funded and do not require NHS eligibility, making them accessible to a broader population at additional cost.

Private treatment suits individuals who fall outside current NHS criteria or who prefer not to wait for the phased rollout to reach their eligibility band. However, patients should ensure they use reputable providers who conduct proper medical assessments and provide appropriate ongoing monitoring.

Rollout timeline for NHS weight loss injections

The NHS rollout of weight loss medications follows a structured timeline designed to manage demand and ensure access for those with greatest clinical need. Understanding this timeline helps patients set realistic expectations about when they might become eligible for treatment.

1. September 2023: Wegovy (semaglutide) becomes available on the NHS for eligible patients with obesity.
2. March 2025: Mounjaro (tirzepatide) rollout begins through specialist services, initially for highest-need patients.
3. June 2025: Various integrated care systems announce expanded access for patients meeting initial Mounjaro criteria.
4. 2027: Target for Mounjaro expansion to BMI 35+ threshold, reaching approximately 220,000 patients.
5. April 2026: Wegovy gains approval for cardiovascular risk reduction in patients with BMI 27+ and existing CVD.
6. Ongoing: Gradual expansion of all medications based on supply capacity and clinical outcomes.

The phased approach reflects both the demand for these treatments and the capacity of specialist services to assess, prescribe, and monitor patients. High demand combined with limited specialist resources means the full rollout to all eligible populations may extend over several years.

What is confirmed versus unclear about NHS weight loss injection access?

The broader context of NHS weight loss injection provision

The introduction of weight loss injections onto the NHS reflects the growing recognition of obesity as a significant health challenge requiring medical intervention alongside lifestyle modification. These medications represent a new category of treatment that addresses the biological drivers of appetite and weight gain rather than relying solely on willpower and dietary restriction.

The NHS approach prioritises patients with the highest medical need, reflecting both clinical evidence about benefit and practical constraints on healthcare resources. Obesity affects millions of people across the UK and contributes to numerous serious health conditions including type 2 diabetes, cardiovascular disease, and certain cancers.

By restricting initial access to those with severe obesity and multiple health complications, the NHS aims to target treatment where clinical benefit is most pronounced. The phased rollout allows for learning about real-world implementation and outcomes before expanding access more broadly.

Healthcare professional perspectives on weight loss injections

Healthcare professionals have emphasised that weight loss injections represent one component of a comprehensive weight management approach. According to guidance from clinical commissioning groups, these medications should be used alongside dietary changes, increased physical activity, and behavioural support.

“Weight management medicines can help people who have found it difficult to lose weight through diet and exercise alone. They work alongside a reduced-calorie diet and increased physical activity.”

— NHS clinical guidance on obesity treatment

Specialist services play a crucial role in patient selection, prescribing, and monitoring. These teams include dietitians, psychologists, and physicians who can address the multifaceted nature of obesity and support patients throughout their treatment journey.

Healthcare professionals also note the importance of addressing underlying factors contributing to weight gain and ensuring patients have realistic expectations about treatment outcomes. The goal is sustainable weight loss supported by lifestyle changes rather than dependence on medication alone.

Summary and next steps for patients

Accessing weight loss injections through the NHS requires meeting specific BMI thresholds, having documented weight-related health conditions, and obtaining a referral to specialist tier 3 weight management services. The three available medications—Mounjaro, Wegovy, and Saxenda—each have distinct eligibility criteria and rollout timelines.

Patients who believe they may qualify should discuss their situation with their GP, who can assess their eligibility and initiate the referral process if appropriate. Those who do not meet current NHS criteria or wish to access treatment more quickly may consider private healthcare options, though this involves additional costs.

For more information on related health topics, readers may find our article on Tai Chi classes for seniors useful for understanding complementary approaches to health management.

Frequently asked questions